Olmesartan Medoxomilo + Hidroclorotiazida Viatris (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxil, the active ingredient in Olmesartan Medoxomilo + Hidroclorotiazida Viatris, is an angiotensin II receptor blocker presented as a oral tablet for hypertension management in adults. It combines olmesartan medoxil with hydrochlorothiazide to lower blood pressure through dual mechanisms.

GNH USA supplies Olmesartan Medoxomilo + Hidroclorotiazida Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan medoxil/hydrochlorothiazide is indicated for cardiovascular conditions that involve elevated blood pressure and fluid retention. - Hypertension: improves blood pressure control when monotherapy is insufficient. - Congestive heart failure: assists in reducing preload and afterload, supporting symptom management. - Diabetic nephropathy: helps protect renal function by controlling systemic hypertension. - Post‑myocardial infarction: contributes to secondary prevention by maintaining target blood pressure levels.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Increased urination - Electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal discomfort

Serious or Rare Side Effects: - Severe hypotension - Acute kidney injury - Hyperkalemia - Angio‑edema - Liver function abnormalities - Blood cell disorders such as agranulocytosis

Before initiating therapy, consider the following safety measures: - Renal function: assess baseline creatinine and eGFR. - Electrolyte balance: monitor potassium and sodium levels regularly. - Pregnancy: avoid use; drug is contraindicated in the second and third trimesters. - Concomitant NSAIDs: use with caution due to increased risk of renal impairment. - Gout: monitor uric acid as thiazides may precipitate attacks. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Olmesartan medoxil/hydrochlorothiazide may interact with several drug classes. Review the following:

Major Interactions (Avoid): - Aliskiren: combined use can cause excessive potassium loss and renal dysfunction. - Potassium‑sparing diuretics or supplements: risk of hyper‑kalemia. - Lithium: increased lithium levels may lead to toxicity.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive effect and affect renal function. - ACE inhibitors or ARBs: additive potassium elevation. - Antidiabetic agents: may require dose adjustment due to enhanced glucose lowering.